Webinar: CRISPR – Tips and Tricks for Efficient Delivery into Primary Cells and Cell Lines

Date: 29 May 2018 Location: Online event City: Online event Country: Online event
Genome editing

Available for On-Demand Viewing 


Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research, medicine, and biotechnology. Compared to other gene editing technologies (e.g. ZFNs and TALENs), it is simpler to re-engineer, easier to use, has broad versatility, and can target multiple sites. One essential factor enabling to explore the full CRISPR potential is efficient delivery of its components into physiologically relevant cell types.


Many renowned scientists are already using Lonza’s non-viral Nucleofector™ Technology for delivering CRISPR plasmids or RNPs efficiently into various cell types. In this webinar, we discuss best practices to achieve optimal delivery results.




Webinar Speaker Dr. Elke Lorbach, Lonza            




Key learning objectives:

  • Understand the basic principle of CRISPR-based genome editing and its potential applications or modes of use    
  • Learn how to achieve efficient delivery into hard-to-transfect cell lines, primary cells or stem cells    
  • Get tips and tricks for using the Nucleofector™ Technology as a powerful non-viral delivery method



Register to watch       

Speaker: Dr. Elke Lorbach

Scientific Support Specialist

Lonza Pharma&Biotech

Bioscience Solutions


View biography Dr. Elke Lorbach studied Biology at the University of Cologne, Germany, and finished her PhD in the Institute of Genetics in the year 2000. Working for many years as a senior scientist and research group leader first with Amaxa and then with Lonza, she has not only been involved in the development of the Nucleofector™ Technology but also gained broad lab experience in the field of cell culture, transfection and genome editing.

Today Elke is a member of Lonza’s Scientific Support Team, sharing her extensive knowledge about transfection and other Lonza products.




Learn more about CRISPR-based genome editing using Lonza's Nucleofector™ Technology.